Please login to the form below

Not currently logged in

FDA turns down Teva's Huntington's disease drug

Has requested further analysis on certain metabolites of the chorea candidate

Teva has been knocked back by an FDA decision not to approve deutetrabenazine, its candidate drug for chorea associated with Huntington's disease.

The US regulator issued a complete response letter (CRL) for deutetrabenazine (SD-809) that has asked the Israeli pharma company to carry out further testing on certain metabolites seen after dosing with the drug.

Teva's drug is a 'deuterated' form of VMAT-2 inhibitor tetrabenazine - the active ingredient in Lundbeck's already-approved Xenazine product - with a modified structure that seeks to improve the safety and efficacy of the parent molecule.

Xenazine is the only approved treatment for Huntington's disease - a rare and fatal neurodegenerative disorder that affects about 1 in 7,000-10,000 people in western countries.

The product brought in around $330m in sales for Lundbeck last year, thanks to its price tag of more than $85,000 a year. 2015 sales of the product rose 30% on the prior year, although it started to face generic competition in the US in the fourth quarter.

In a statement, Teva said that the metabolites under scrutiny by the FDA are not novel, and are also seen in patients who take tetrabenazine. The company said the agency has not requested any new clinical trials, adding that it will work to allay its concerns "as quickly as possible".

It is estimated that because of tolerability issues only around 5% of eligible Huntington's disease patients in the US receive tetrabenazine treatment. In trials deutetrabenazine was associated with lower rates of depression, somnolence, insomnia and akathisia, which could expand its use in this patient population.

"We know that many people in the [Huntington's] community are waiting for this new medicine," commented Teva's chief scientific officer Michael Hayden.

"We understand there are very limited treatment options … hence we are accelerating the re-analysis process [and] plan to submit our response to the CRL in the third quarter," he added.

The metabolites issue is critical for Teva as it is also developing deutetrabenazine for other uses, notably tardive dyskinesia, a much larger indication which has no approved therapies in the US, and tics associated with Tourette's syndrome.

Teva acquired deutetrabenazine when it bought Auspex Pharma for $3.5bn in March 2015.

Article by
Phil Taylor

1st June 2016

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...